Stefan Agewall (S Agewall)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 43

Top Topics

Antiplatelet Therapy

Magnetic Resonance

Cardiovascular Disease

St Segment Elevation Myocardial Infarction

Top Venues

European heart journal. Cardiovascular pharmacotherapy

Journal of the American Heart Association

European heart journal

Circulation research

This page only lists publications with an associated author ORCID identifier.

Publications

Anton Håkansson, Sasha Koul, Elmir Omerovic, Jonas Andersson, Stefan K James, Stefan Agewall, Arash Mokhtari, Jesper van Der Pals, Axel Wester, Karolina Elisabeth Szummer, Tomas Jernberg, David Erlinge, Moman Aladdin Mohammad
Abbreviated Versus Standard Dual Antiplatelet Therapy Times After Percutaneous Coronary Intervention in Patients With High Bleeding Risk With Acute Coronary Syndrome: Insights From the SWEDEHEART Registry. Journal of the American Heart Association 13 (13) (2024)
Nidhi Singh, Ashtyn Tracey Areal, Susanne Breitner, Siqi Zhang, Stefan Agewall, Tamara Schikowski, Alexandra Schneider
Heat and Cardiovascular Mortality: An Epidemiological Perspective. Circulation research 134 (9) (2024)
Nidhi Singh, Ashtyn Tracey Areal, Susanne Breitner, Siqi Zhang, Stefan Agewall, Tamara Schikowski, Alexandra Schneider
Heat and Cardiovascular Mortality: An Epidemiological Perspective. Circulation research 134 (9) (2024)
Nidhi Singh, Ashtyn Tracey Areal, Susanne Breitner, Siqi Zhang, Stefan Agewall, Tamara Schikowski, Alexandra Schneider
Heat and Cardiovascular Mortality: An Epidemiological Perspective. Circulation research 134 (9) (2024)
Anton Håkansson, Sasha Koul, Elmir Omerovic, Jonas Andersson, Stefan K James, Stefan Agewall, Arash Mokhtari, Jesper van Der Pals, Axel Wester, Karolina Elisabeth Szummer, Tomas Jernberg, David Erlinge, Moman Aladdin Mohammad
Abbreviated Versus Standard Dual Antiplatelet Therapy Times After Percutaneous Coronary Intervention in Patients With High Bleeding Risk With Acute Coronary Syndrome: Insights From the SWEDEHEART Registry. Journal of the American Heart Association 13 (13) (2024)
Anton Håkansson, Sasha Koul, Elmir Omerovic, Jonas Andersson, Stefan K James, Stefan Agewall, Arash Mokhtari, Jesper van Der Pals, Axel Wester, Karolina Elisabeth Szummer, Tomas Jernberg, David Erlinge, Moman Aladdin Mohammad
Abbreviated Versus Standard Dual Antiplatelet Therapy Times After Percutaneous Coronary Intervention in Patients With High Bleeding Risk With Acute Coronary Syndrome: Insights From the SWEDEHEART Registry. Journal of the American Heart Association 13 (13) (2024)
Anton Håkansson, Sasha Koul, Elmir Omerovic, Jonas Andersson, Stefan K James, Stefan Agewall, Arash Mokhtari, Jesper van Der Pals, Axel Wester, Karolina Elisabeth Szummer, Tomas Jernberg, David Erlinge, Moman Aladdin Mohammad
Abbreviated Versus Standard Dual Antiplatelet Therapy Times After Percutaneous Coronary Intervention in Patients With High Bleeding Risk With Acute Coronary Syndrome: Insights From the SWEDEHEART Registry. Journal of the American Heart Association 13 (13) (2024)
Stefan Agewall
New data on NOVEL ORAL ANTICOAGULANT, SGLT2i, lipid treatment and genetics. European heart journal. Cardiovascular pharmacotherapy (2024)
Stefan Agewall
New data on NOVEL ORAL ANTICOAGULANT, SGLT2i, lipid treatment and genetics. European heart journal. Cardiovascular pharmacotherapy 10 (2) (2024)
Bruna Gigante, Juan Tamargo, Stefan Agewall, Dan Atar, Jurrien Ten Berg, Gianluca Calogero Campo, Elisabetta Cerbai, Christina Christersson, Dobromir Dobrev, Peter Ferdinandy, Tobias Geisler, Diana Adrienne Gorog, Erik Lerkevang Grove, Juan Carlos Kaski, Andrea Rubboli, Sven Wassmann, Håkan Wallen, Bianca Rocca
Update on antithrombotic therapy and body mass. A Clinical consensus Statement of the ESC Working Group on Cardiovascular Pharmacotherapy and the ESC Working Group on Thrombosis. European heart journal. Cardiovascular pharmacotherapy (2024)
Per Tornvall, John F Beltrame, Jannike Nickander, Peder Sörensson, Harmony R Reynolds, Stefan Agewall
How to Use Cardiac Magnetic Resonance Imaging in Myocardial Infarction With Nonobstructive Coronary Arteries. Circulation. Cardiovascular imaging 17 (7) (2024)
Stefan Agewall
Special focus on the new anti-diabetic drugs. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Stefan Agewall
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Anton Håkansson, Sasha Koul, Elmir Omerovic, Jonas Andersson, Stefan K James, Stefan Agewall, Arash Mokhtari, Jesper van Der Pals, Axel Wester, Karolina Elisabeth Szummer, Tomas Jernberg, David Erlinge, Moman Aladdin Mohammad
Abbreviated Versus Standard Dual Antiplatelet Therapy Times After Percutaneous Coronary Intervention in Patients With High Bleeding Risk With Acute Coronary Syndrome: Insights From the SWEDEHEART Registry. Journal of the American Heart Association (2024)
Stefan Agewall
Antiplatelet treatment after PCI. European heart journal. Cardiovascular pharmacotherapy (2023)
Stefan Agewall
A tailor-made suit always fits best. European heart journal. Cardiovascular pharmacotherapy 9 (3) (2023)
Stefan Agewall
Cardiovascular preventive actions. European heart journal. Cardiovascular pharmacotherapy 9 (6) (2023)
Stefan Agewall
Focus on lipid treatment. European heart journal. Cardiovascular pharmacotherapy 9 (2) (2023)
Heinz Drexel, Christoph H Saely, Stefan Agewall
Fibrates: one more lost paradise in lipid treatment. European heart journal. Cardiovascular pharmacotherapy 9 (2) (2023)
Stefan Agewall
The search for the perfect antiplatelet treatment continues. European heart journal. Cardiovascular pharmacotherapy 9 (8) (2023)
Stefan Agewall
Focus on lipid treatment. European heart journal. Cardiovascular pharmacotherapy 9 (2) (2023)
Juan Tamargo, Stefan Agewall
Concerns about aortic aneurysm or dissection risk should not cease fluoroquinolone use when clinically indicated. European heart journal (2023)
Stefan Agewall
Cardiovascular prevention and risk factors. European heart journal. Cardiovascular pharmacotherapy (2023)
Stefan Agewall
The search for the perfect antiplatelet treatment continues. European heart journal. Cardiovascular pharmacotherapy 9 (8) (2023)
Heinz Drexel, Christoph H Saely, Stefan Agewall
Fibrates: One more lost paradise in lipid treatment. European heart journal. Cardiovascular pharmacotherapy (2023)
Maria Lukács Krogager, Kristian Kragholm, Jesper Qvist Thomassen, Peter Søgaard, Basil S Lewis, Sven Wassmann, Iris Baumgartner, Claudio Ceconi, Thomas Andersen Schmidt, Juan-Carlos Kaski, Heinz Drexel, Anne Grete Semb, Stefan Agewall, Alexander Niessner, Gianluigi Savarese, Keld Per Kjeldsen, Claudio Borghi, Juan Tamargo, Christian Torp-Pedersen
Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European heart journal. Cardiovascular pharmacotherapy 7 (6) (2022)
Stefan Agewall
Future of European Heart Journal Cardiovascular Pharmacotherapy. European heart journal. Cardiovascular pharmacotherapy 8 (8) (2022)
Stefan Agewall
Pharmacological treatment of CVD. European heart journal. Cardiovascular pharmacotherapy 9 (1) (2022)
Stefan Agewall
Adherence to pharmacological treatment: how can we improve? European heart journal. Cardiovascular pharmacotherapy 7 (4) (2022)
Stefan Agewall
Different aspects of giving the optimal antiplatelet treatment. European heart journal. Cardiovascular pharmacotherapy 7 (3) (2022)
Stefan Agewall
Treatment with dual antiplatelet therapy after an acute coronary event may often be tailor-made for the patient. European heart journal. Cardiovascular pharmacotherapy 8 (1) (2022)
Juan Tamargo, Koji Hasegawa, Stefan Agewall
Toward personalized medicine for cardiovascular pharmacotherapy. European heart journal 43 (45) (2022)
Stefan Agewall
Pharmacological treatment of CVD. European heart journal. Cardiovascular pharmacotherapy 9 (1) (2022)
Stefan Agewall
More knowledge about atrial fibrillation, still we need to learn. European heart journal. Cardiovascular pharmacotherapy 7 (5) (2022)
Stefan Agewall
Treating patients with anticoagulants and antiplatelet drugs is always a balance between risk for thrombosis vs. risk for bleeding. European heart journal. Cardiovascular pharmacotherapy 8 (7) (2022)
Heinz Drexel, Basil S Lewis, Giuseppe M C Rosano, Christoph H Saely, Gerda Tautermann, Kurt Huber, Joern F Dopheide, Juan Carlos Kaski, Arthur Mader, Alexander Niessner, Gianluigi Savarese, Thomas A Schmidt, AnneGrete Semb, Juan Tamargo, Sven Wassmann, Keld Per Kjeldsen, Stefan Agewall, Stuart J Pocock
The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials. European heart journal. Cardiovascular pharmacotherapy 7 (5) (2022)
Stefan Agewall
Optimizing individual heart failure treatment. European heart journal. Cardiovascular pharmacotherapy 8 (2) (2022)
Stefan Agewall
Prevention is still the key to success. European heart journal. Cardiovascular pharmacotherapy 8 (6) (2022)
Stefan Agewall
To treat or not to treat. European heart journal. Cardiovascular pharmacotherapy 8 (8) (2022)
Stefan Agewall
Unsolved pharmacological issues with cardiology. European heart journal. Cardiovascular pharmacotherapy 7 (6) (2022)
Juan Tamargo, Juan Carlos Kaski, Takeshi Kimura, Jack Charles Barton, Ko Yamamoto, Maki Komiyama, Heinz Drexel, Basil S Lewis, Stefan Agewall, Koji Hasegawa
Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events. European heart journal. Cardiovascular pharmacotherapy 8 (7) (2022)
Stefan Agewall
Focus on optimizing treatment of coronary heart disease. European heart journal. Cardiovascular pharmacotherapy 8 (5) (2022)
Juan Tamargo, Stefan Agewall
Fluoroquinolone use and valvular heart disease: is the jury still out? European heart journal 42 (30) (2021)